News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation and Priaxon Announce a Collaboration to Research and Develop Novel Treatments for Cancer


1/19/2010 10:39:52 AM

MUNICH & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions. p53 is a human tumor suppressor protein. It has been shown that in tumors with wild-type p53, the restoration of p53 tumor-suppressive functions can be achieved by blocking a cellular interaction of mdm21 and p53. This may reactivate the “genome guardian” function of p53 and is therefore an interesting approach for treating various oncological indications.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES